Moderna's Stock Slides 2.43% as Patent Settlement Sends Trading Volume to 206th Rank

Market Snapshot

On March 6, 2026, Moderna Inc. (NASDAQ: MRNA) closed with a 2.43% decline, marking its second consecutive day of losses. The stock traded with a volume of $0.63 billion, ranking 206th in daily trading activity. This performance followed a significant 16% surge in early March after the company announced a $2.25 billion settlement to resolve a four-year patent dispute with Arbutus Biopharma and Genevant Sciences.

Key Drivers

Moderna’s recent stock volatility reflects the resolution of a protracted legal battle over lipid nanoparticle (LNP) technology central to its Spikevax and mRESVIA vaccines. Under the settlement, the company agreed to pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on the outcome of a federal court appeal. This agreement, reached days before a scheduled jury trial, eliminated a major legal overhang and provided clarity on future royalty obligations. Moderna emphasized that no ongoing royalties will be required for its mRNA vaccines, a critical factor for long-term profitability.

The settlement’s financial terms were perceived as favorable compared to initial investor fears of higher liabilities. Analysts noted that the $2.25 billion total payment represents a manageable burden, especially given Moderna’s $48 billion in cumulative vaccine sales. Jefferies analysts highlighted the effective 2%–5% royalty rate implied by the settlement, significantly lower than potential double-digit rates had the dispute escalated. Additionally, the agreement grants Moderna a non-exclusive license to Genevant’s LNP technology, ensuring continued access to critical delivery systems for its infectious disease portfolio.

Despite the favorable resolution, the stock’s recent decline on March 6 suggests lingering market concerns. While the settlement removes immediate legal risks, contingent payments tied to the Federal Circuit’s decision on government-contractor immunity could still materialize. If the court affirms liability under Section 1498, Moderna may face an additional $1.3 billion payment within 90 days. Bernstein analyst Courtney Breen warned that such an outcome could reduce cash reserves to as low as $3.2 billion by year-end, narrowing Moderna’s financial flexibility.

Looking ahead, the settlement positions Moderna to focus on its oncology pipeline and next-generation vaccines. The company anticipates ending 2026 with $4.5 billion to $5 billion in cash and cash equivalents, bolstered by access to a $900 million credit facility. William Blair analyst Myles Minter emphasized that late-stage oncology trials expected this year represent key growth drivers, reducing reliance on declining pandemic-era vaccine sales. Additionally, regulatory progress on a combination influenza-COVID vaccine and mNexspike, a next-generation COVID shot, further strengthens Moderna’s long-term prospects.

The broader patent litigation landscape, however, remains complex. Arbutus and Genevant continue pursuing similar claims against Pfizer and BioNTech, while Moderna’s own patent lawsuit against its rivals complicates the competitive environment. These ongoing legal battles underscore the high-stakes nature of intellectual property in the mRNA vaccine space. For now, the settlement with Arbutus and Genevant provides a near-term resolution, but investors will closely monitor future rulings and the pace of Moderna’s pipeline advancements to assess long-term value.